Replies to post #25037 on Mymetics Corp (MYMX)

[bow-tie]

HER-Vaxx Re-Formulation Shows Dramatic Ten-Fold Increase in ...
www.asx.com.au › asxpdf › 20150420
immunizations), compared with the earlier virosome-based formulation of HER-Vaxx. HER-Vaxx stimulates a polyclonal antibody response to HER-2/neu, the oncogene which is targeted by the currently used monoclonal antibody Herceptin®. Further, on Friday 17th April, the Company filed new patent applications around the new

https://www.asx.com.au/asxpdf/20150420/pdf/42xzdym1slg09p.pdf

[Work Harder]

Patent that shows MYMX is manufacturing the combination using Bachem's P647 Peptide, combined with the monoxide CRM197 from Merck!

Seppic, France

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135820672

Imugene went w/ Bachem

I want to know who the oncology partner in the Netherlands is

& if I don't see it before much longer this thing could get nasty